Biomarkers of Interstitial Cystitis/Bladder Pain Syndrome
Author Information
Author(s): Kuret Tadeja, Sterle Igor, Romih Rok, Veranič Peter
Primary Institution: Institute of Cell Biology, Faculty of Medicine, University of Ljubljana, Slovenia
Hypothesis
The study aims to identify matched serum- and urine-derived biomarkers of interstitial cystitis/bladder pain syndrome (IC/BPS) to provide insights into disease mechanisms and support further biomarker validation.
Conclusion
The study identified several biomarkers that can differentiate IC/BPS patients from healthy controls, with MMP9 showing potential as a target for therapeutic interventions.
Supporting Evidence
- Four biomarkers, including CCL11, BAFF, HGF, and MMP9, were significantly upregulated in both serum and urine of patients with IC/BPS compared to controls.
- Serum levels of MMP9 were associated with disease severity and could distinguish well between IC/BPS patients with and without Hunner’s lesions.
- Utilizing a comprehensive panel of both urine and serum biomarkers holds promise for disease detection in IC/BPS patients.
Takeaway
Doctors are trying to find special markers in blood and urine that can help diagnose a painful bladder condition called IC/BPS, which is hard to identify.
Methodology
The study measured 33 different biomarkers in serum and urine samples from 12 IC/BPS patients and 12 healthy controls using enzyme-linked immunoassays and multiplex technology.
Potential Biases
Potential selection bias due to the age difference between patients and controls.
Limitations
The study had a small sample size and included only female participants, which may limit the generalizability of the findings.
Participant Demographics
12 female patients with IC/BPS and 12 healthy female controls.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website